User menu

Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.

Bibliographic reference Devogelaer, Jean-Pierre ; Bergmann, P. ; Body, J-J ; Boutsen, Yves ; Goemaere, S. ; et. al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.. In: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, Vol. 19, no. 8, p. 1109-17 (2008)
Permanent URL http://hdl.handle.net/2078.1/12607
  1. Paget James, On a Form of Chronic Inflammation of Bones (Osteitis Deformans), 10.1177/095952877706000105
  2. Hosking D., Meunier P. J, Ringe J. D, Reginster J.-Y., Gennari C., Fortnightly Review: Paget's disease of bone: diagnosis and management, 10.1136/bmj.312.7029.491
  3. Delmas PD, Meunier PJ (1997) Drug therapy: the management of Paget’s disease of bone. N Engl J Med 336:558–566
  4. Lyles KW, Siris ES, Singer FR, Meunier PJ (2001) Perspective. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res 16(8):1379–1387
  5. Selby PL, Davie MWJ, Ralston SH, Stone MD (2002) Guidelines on the management of Paget’s disease of bone. Bone 31(3):10–19
  6. Scarsbrook A, Brown M, Wilson D (2004) UK guidelines on management of Paget’s disease of bone. Rheumatology 43:399–400
  7. Langston AL, Ralston SH (2004) Management of Paget’s disease of bone. Rheumatology 43:955–959
  8. Whyte MP (2006) Paget’s disease of bone. N Engl J Med 355:593–600
  9. US Department of Health and Human Services. Agency for Health care policy and research (1993) Acute pain management: operative or medical procedures and trauma. Clinical Practice Guidelines n°1. AHCPR Publication # 92–0023, p 107
  10. Devogelaer JP, Nagant de Deuxchaisnes C (2003) Paget’s disease of bone. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology, vol 2, 3rd edn. Mosby, London, pp 2139–2147
  11. Barker DJ, Clough PW, Guyer PB, Gardner MJ (1977) Paget’s disease of bone in 14 British towns. Br Med J 1:1181–1183
  12. Cooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D (1999) The epidemiology of Paget’s disease in Britain: is the prevalence decreasing ? J Bone Miner Res 14:192–197
  13. Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T (2004) Paget’s disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 75:358–364
  14. Morales-Piga AA, Bachiller-Corral FJ, Abraira V, Beltran J, Rapado A (2002) Is clinical expressiveness of Paget’s disease of bone decreasing ? Bone 30:399–403
  15. Rapado A., Jimenez J., Morales A., Carbonell J., Pino J. Del, Patterns of diagnosis of paget's disease in spain, 10.1002/jbmr.5650140220
  16. Tiegs RD, Lohse CM, Wollan PC, Melton LJ (2000) Long-term trends in incidence of Paget’s disease of bone. Bone 27:423–427
  17. Gennari L, Di Stefano M, Merlotti D et al (2005) Prevalence of Paget’s disease of bone in Italy. J Bone Miner Res 20:1845–1850
  18. Detheridge FM, Guyer PB, Barker DJP (1982) European distribution of Paget’s disease of bone. Br Med J 285:1005–1008
  19. Lucas GJA, Daroszewskia A, Ralston SH (2006) Contribution of genetic factors to the pathogenesis of Paget’s disease of bone and related disorders. J Bone Miner Res 21 [Suppl 2]:P31–P37
  20. Collins DH (1956) Paget’s disease of bone. Incidence and subclinical forms. Lancet 2:51–57
  21. Altman RD (1980) Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 23:1121–1127
  22. Fernandez S, Tiessen L, Powell-Tuck J, Beck S, Johansen A (2007) Pagetic hip fracture. How big is the problem? Osteoporos Int 18 [Suppl 3]:S292
  23. Sundaram M (2006) Imaging of Paget’s disease and fibrous dysplasia. J Bone Miner Res 21 [Suppl 2]:P28–P30
  24. Maldague B, Malghem J (1987) Dynamic radiologic patterns of Paget’s disease of bone. Clin Orthop 217:126–151
  25. Meunier PJ, Vignot E (1995) Therapeutic strategy in Paget’s disease of bone. Bone 17 [Suppl 5]:489S–491S
  26. Siris ES, Lyles KW, Singer FR, Meunier PJ (2006) Medical management of Paget’s disease of bone. Indications for treatment and review of current therapies. J Bone Miner Res 21 [Suppl 2]:P94–P98
  27. Nagant de Deuxchaisnes C, Devogelaer JP (1989) Surveillance et suivi à long terme de la maladie osseuse de Paget. In: Simon L, Sébert JL, Hérisson C (eds) La maladie osseuse de Paget: actualités. Masson, Paris
  28. Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. Dunitz, London
  29. Van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471
  30. Gold Deborah T., Burchett Bruce M., Shipp Kathy M., Pieper Carl F., Lyles Kenneth W., Factors associated with self-rated health in patients with paget's disease of bone, 10.1002/jbmr.5650140221
  31. Ralston SH, Langston AL, Campbell MK, MacLennan G, Selby PL, Fraser WD (2006) Initial results from the PRISM study: a large randomised comparative trial of intensive versus symptomatic treatment for Paget’s disease. J Bone Miner Res 21 [Suppl 1]:LB1
  32. Langston AL, Campbell MK, Fraser WD, MacLennan G, Selby P, Ralston SH for the PRISM Trial Group (2007) Clinical determinants of quality of life in Paget’s disease of bone. Calcif Tissue Int 80:1–9
  33. Russell RG, Smith R, Preston C, Walton RJ, Woods CG (1974) Diphosphonates in Paget’s disease. Lancet 1:894–898
  34. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 41:354–360
  35. Reid IR, Davidson JS, Wattie D et al (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 35:224–230
  36. Shankar S, Hosling DJ (2006) Biochemical assessment of Paget’s disease of bone. J Bone Miner Res 21[Suppl 2]:P22–P27
  37. Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M (2005) 18F-fluoride PET for monitoring therapeutic response in Paget’s disease of bone. J Nucl Med 46:1650–1658
  38. Nagant de Deuxchaisnes C, Maldague B, Malghem J, Devogelaer JP, Huaux JP, Rombouts-Lindemans C (1980) The action of the main therapeutic regimes on Paget’s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 23:1215–1234
  39. Margiloff L, Harris SS, Lee S, Lechan R, Dawson-Hughes B (2001) Vitamin D status of an outpatient clinic population. Calcif Tissue Int 69:263–267
  40. Chapuy M-C, Zucchelli P, Meunier PJ (1982) La fonction parathyroïdienne dans la maladie osseuse de Paget. Rev Rhum Mal Osteoartic 49:99–102
  41. Siris ES, Clemens TP, McMahon D, Gordon A, Jacobs TP, Canfield RE (1989) Parathyroid function in Paget’s disease of bone. J Bone Miner Res 4:75–79
  42. Fenton AJ, Gutteridge DH, Kent GN et al (1991) Intravenous aminobisphosphonate in Paget’s disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol (Oxf) 34:197–204
  43. Frijlink W, Bijvoet O, Te Velde J, Heynen G (1979) Treatment of Paget’s disease with 3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet i:799–803
  44. Siris E (1995) Paget’s disease of bone. J Clin Endocrinol Metab 80:335–338
  45. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423
  46. DeRose J, Singer FR, Avramides A et al (1974) Response of Paget’s disease to porcine and salmon calcitonins: effects of long-term treatment. Am J Med 56:858–866
  47. Devogelaer JP (2002) Modern therapy for Paget’s disease of bone. Focus on bisphosphonates. Treat Endocrinol 1:241–257
  48. Delmas P, Meunier PJ (1997) The management of Paget’s disease of bone. N Engl J Med 336:558–566
  49. Siris E, Canfield R, Jacobs T, Stoddart K, Spector T (1981) Clinical and biochemical effects of EHDP in Paget’s disease of bone: patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res 3:301–308
  50. Canfield R, Rosner W, Skinner J et al (1977) Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 44:96–106
  51. KHAIRI M. R. A., Sodium Etidronate in the Treatment of Paget's Disease of Bone : A Study of Long-Term Results, 10.7326/0003-4819-87-6-656
  52. Altman RD (1985) Long-term follow-up of therapy with intermittent etidronate disodium in Paget’s disease of bone. Am J Med 79:583–590
  53. Yates AJP, Percival RC, Gray RES et al (1985) Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1:1474–1477
  54. Siris ES, Chines AA, Altman RD et al (1998) Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032–1038
  55. Reid I, Nicholson GC, Weinstein R (1996) Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 101:341–348
  56. Gray RES, Yates AJP, Preston CJ, Smith R, Russell RGG, Kanis JA (1987) Duration of effect of oral diphosphonate therapy in Paget’s disease of bone. Q J Med 64:755–767
  57. Siris E, Weinstein RS, Altman R et al (1996) Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab 81:961–967
  58. Roux C, Gennari C, Farrerons J et al (1995) Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget’s disease of bone. Arthritis Rheum 38:851–858
  59. Peris P, Alvarez L, Vidal S, Martinez MA, Monegal A, Guañabens N (2007) Treatment with tiludronate has a similar effect to risedronate on Paget’s disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheum 25:206–210
  60. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, for the Paget’s risedronate/etidronate study group (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 106:513–520
  61. Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P (1989) Une perfusion unique de pamidronate (APD) dans la maladie de Paget de l’os. Schweiz Med Wochenschr 119:71–74
  62. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyle BF (1993) Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 342:1459–1460
  63. Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 308:226–233
  64. Reid IR, Miller P, Lyles K et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908
  65. Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289
  66. Hosking D, Lyles K, Brown J et al (2007) Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142–148
  67. Lecomte P, Devogelaer JP, Kaufman JM, Goemaere S, Geusens P, Engbersen A, PMD2 COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM, 10.1016/s1098-3015(10)67367-6
  68. Kurth AA, Kotowa W, Fricke FU, Quednau K, Maiwenn JA, PAR2 ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY-A COSTSAVING APPROACH?, 10.1016/s1098-3015(10)63261-5